NOVARTIS AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 99.48 USD | +1.51% |
|
+1.50% | -0.52% |
| 04:03pm | NOVARTIS AG : Jefferies remains its Buy rating | ZD |
| 03:26pm | Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 734B | ||||||
| 591B | ||||||
| 350B | ||||||
| 315B | ||||||
| 276B |
